Advertisement
Australia markets closed
  • ALL ORDS

    7,974.80
    -27.70 (-0.35%)
     
  • ASX 200

    7,724.30
    -25.40 (-0.33%)
     
  • AUD/USD

    0.6616
    -0.0022 (-0.32%)
     
  • OIL

    79.02
    +0.40 (+0.51%)
     
  • GOLD

    2,349.50
    +31.50 (+1.36%)
     
  • Bitcoin AUD

    101,234.34
    -1,154.65 (-1.13%)
     
  • CMC Crypto 200

    1,426.18
    +8.31 (+0.59%)
     
  • AUD/EUR

    0.6187
    +0.0014 (+0.23%)
     
  • AUD/NZD

    1.0780
    +0.0028 (+0.26%)
     
  • NZX 50

    11,864.89
    -7.75 (-0.07%)
     
  • NASDAQ

    19,576.92
    +111.74 (+0.57%)
     
  • FTSE

    8,151.81
    -11.86 (-0.15%)
     
  • Dow Jones

    38,647.10
    -65.11 (-0.17%)
     
  • DAX

    18,067.09
    -198.59 (-1.09%)
     
  • Hang Seng

    17,941.78
    -170.85 (-0.94%)
     
  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     

Director David Gill Sells 10,361 Shares of Evolus Inc (EOLS)

On May 14, 2024, David Gill, Director at Evolus Inc (NASDAQ:EOLS), executed a sale of 10,361 shares of the company. The transaction was filed on the same day with the SEC. Following this transaction, the insider has a total of 0 shares remaining in the company.

Evolus Inc (NASDAQ:EOLS) is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. Its primary product, Jeuveau, is used in cosmetic treatments for improving the appearance of facial lines.

The shares were sold at a price of $12.64, valuing the transaction at approximately $130,768.64. This sale has adjusted the insider's stake in Evolus Inc significantly.

ADVERTISEMENT

Over the past year, the insider transaction history at Evolus Inc shows a trend with 1 insider buy and 19 insider sells. The recent sale by the insider is part of a broader pattern observed within the company's trading activity.

As of the latest trading session, Evolus Inc (NASDAQ:EOLS) has a market cap of approximately $828.963 million. The stock's valuation metrics, such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, are derived from historical trading multiples and an adjustment factor based on the companys past performance and growth.

The current price of $12.64 compared to the GF Value of $14.26 suggests that Evolus Inc is Fairly Valued. The price-to-GF-Value ratio stands at 0.89.

Director David Gill Sells 10,361 Shares of Evolus Inc (EOLS)
Director David Gill Sells 10,361 Shares of Evolus Inc (EOLS)
Director David Gill Sells 10,361 Shares of Evolus Inc (EOLS)
Director David Gill Sells 10,361 Shares of Evolus Inc (EOLS)

This valuation is supported by the GF Value, which is an intrinsic value estimate from GuruFocus. It considers historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates provided by Morningstar analysts.

The recent insider selling activity could be a point of interest for current and potential investors, providing insight into how insiders view the stock's valuation and future prospects.

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

This article first appeared on GuruFocus.